NCT04237649 - KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

September 15, 2023

Study Completion Date

September 15, 2023

Conditions

Solid Tumors

Interventions

DRUG

KAZ954

KAZ954 will be administered in every arm.

DRUG

PDR001

KAZ954 + PDR001

DRUG

NIR178

KAZ954 + NIR178

DRUG

NZV930

KAZ954 + NZV930

Trial Locations (13)

10002

Novartis Investigative Site, Taipei

20133

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

60611

Northwestern University Med School, Chicago

63110

WA Uni School Of Med Dept. of Siteman Cancer Center, St Louis

77030

Uni of TX MD Anderson Cancer Cntr, Houston

90095

University Of California LA, Los Angeles

119074

Novartis Investigative Site, Singapore

06511

Yale University Yale Cancer Center, New Haven

M5G 2M9

Novartis Investigative Site, Toronto

Unknown

Novartis Investigative Site, Shatin New Territories

411 8777

Novartis Investigative Site, Sunto Gun

08035

Novartis Investigative Site, Barcelona